摘要
摘要
INTRODUCTION: Although effective acute migraine therapies are available, unmet treatment needs such as nausea, vomiting, or delayed gastric emptying remain. STS101 is a novel dihydroergotamine (DHE) nasal powder designed to treat acute migraine with a simple single. AREAS COVERED: A targeted PubMed and ClinicalTrials.gov search was performed from database inception through October 2025 using the keywords "STS101," "dihydroergotamine," "migraine," and "intranasal powder." Eligible sources included English-language clinical studies, trial registry records, regulatory documents, and relevant conference abstracts addressing STS101 formulation, pharmacokinetics, efficacy, safety, and/or regulatory development. Data from Phase 1 pharmacokinetic trials, the Phase 3 EMERGE and SUMMIT randomized controlled trials, and the ASCEND long-term safety study are discussed. EXPERT OPINION: The pivotal efficacy trials did not meet their 2-hour co-primary endpoints. Later time-point analyses suggested possible clinical benefit, including higher rates of pain freedom and most bothersome symptom freedom from 3 to 48 hours. STS101 may be useful for some patients who prefer a non-oral intranasal rescue option or have had inadequate responses to triptans, gepants or other DHE forms of administration. Its clinical role will likely depend on how clinicians weigh its delivery platform, DHE pharmacology, tolerability, and place relative to other available intranasal options.
KM 提取结果
0 个 Figure · 0 个 KM 面板